Edwards Lifesciences Corp Quarterly Report for Q1 Ended Mar 31, 2020

Summary

Edwards Lifesciences Corporation reported strong top-line growth in the first quarter of 2020, with net sales increasing by 13.7% to $1.13 billion compared to the prior year. This growth was primarily driven by a significant 24.2% increase in Transcatheter Aortic Valve Replacement (TAVR) sales, largely attributed to the success of the Edwards SAPIEN 3 Ultra valve. Despite the onset of the COVID-19 pandemic in March 2020, which began to impact procedure volumes in the latter half of the quarter, the company demonstrated resilience. Profitability also saw improvement, with net income rising to $310.6 million, a 24.4% increase year-over-year, leading to diluted earnings per share of $1.47, up from $1.18 in the prior year. The company maintained a healthy financial position, although cash and cash equivalents decreased due to substantial share repurchases totaling $614.7 million during the quarter. Management highlighted the impact of COVID-19 as a significant uncertainty for future operations, particularly concerning procedure volumes and supply chain stability.

Key Highlights

• 1Net sales increased by 13.7% to $1.13 billion in Q1 2020 compared to Q1 2019.
• 2Transcatheter Aortic Valve Replacement (TAVR) sales showed robust growth of 24.2%, driven by the Edwards SAPIEN 3 Ultra valve.
• 3Net income rose by 24.4% to $310.6 million, with diluted EPS increasing to $1.47 from $1.18 year-over-year.
• 4The company repurchased $614.7 million of its common stock during the quarter.
• 5Operating activities generated $207.0 million in cash flow, a significant increase from $1.5 million in the prior year.
• 6The company acknowledges significant uncertainty and potential adverse impacts from the COVID-19 pandemic on future operations and demand.
• 7Research and Development expenses increased, reflecting ongoing investment in transcatheter mitral and tricuspid therapies.

Frequently Asked Questions